We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · October 06, 2020

Galcanezumab After Failure of Multiple Previous Migraine Prevention Medications

The Lancet Neurology


Additional Info

The Lancet Neurology
Safety and Efficacy of Galcanezumab in Patients for Whom Previous Migraine Preventive Medication From Two to Four Categories Had Failed (CONQUER): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3b Trial
Lancet Neurol 2020 Oct 01;19(10)814-825, WM Mulleners, BK Kim, MJA Láinez, M Lanteri-Minet, P Pozo-Rosich, S Wang, A Tockhorn-Heidenreich, SK Aurora, RM Nichols, L Yunes-Medina, HC Detke

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading